NUCLIDIUM Closes EUR 84 Million Series B Financing to Advance Clinical Development of its Copper-based Radiopharmaceutical Platform

Led by Dr. Leila Jaafar-Thiel (CEO and Founder), Andreas Schuh(CFO/COO), Ben Pais, MD (CMO), Prof. Dr. Gustav von Schulthess (MD, PhD) (Medical Advisor & Co-Founder), Nuclidium announced Series B financing of EUR 84 Million led by Kurma Growth Opportunities Fund, Angelini Ventures, Wellington Partners, and Neva SGR (Intesa Sanpaolo Group), with participation from DeepTech & Climate Fonds (DTCF), Bayern Kapital, Vives Partners, Eurazeo, and NRW.BANK and HighLight Capital, as well as existing investors. As part of the financing round, Daniel Parera (Kurma Partners), Regina Hodits (Angelini Ventures), and Liliana Nordbakk (Neva SGR) will join NUCLIDIUM’s Board of Directors.

The funding will support clinical development of NUCLIDIUM’s Copper-61/Copper-67 theranostic pipeline in oncology and enable expansion of its global production and manufacturing network.

NUCLIDIUM’s platform pairs tumor-targeting molecules with copper isotopes—Copper-61 for diagnostics and Copper-67 for therapy—to overcome limitations in current radiotheranostics. Early clinical data show superior lesion detection, higher tumor-to-background ratios, and a favorable safety profile for 61Cu-NuriPro™, with promising imaging and therapeutic results in prostate, neuroendocrine, and breast cancers.